GLP-1受体激动剂对肾脏结局的影响:系统综述与Meta分析
该系统综述与Meta分析纳入19项试验共90882例患者,评估GLP-1受体激动剂对肾脏结局的影响。结果显示GLP-1受体激动剂使主要肾脏结局风险降低19%(RR 0.81,95%CI 0.73-0.89),并降低肾功能下降风险及微量白蛋白尿,但进展至肾衰竭无显著差异。
要点
- GLP-1受体激动剂使主要肾脏复合结局风险降低19%(RR 0.81,95%CI 0.73-0.89)。
- GLP-1受体激动剂使微量白蛋白尿降低24%(RR 0.76,95%CI 0.71-0.82)。
- 进展至肾衰竭无显著差异(RR 0.86,95%CI 0.71-1.05),胃肠道副作用更多。
核心结论
- GLP-1受体激动剂显示出心血管和肾脏获益。
- 需要进一步开展高质量随机试验,评估其在无糖尿病患者、伴或不伴蛋白尿和/或CKD患者中的效果。
研究设计与样本
- 系统综述与Meta分析,检索Medline、EMBASE和Cochrane Register至2024年12月。
- 共纳入19项试验,包括90882例患者,平均年龄60.8岁,平均随访25.9个月。
- 主要结局为肾衰竭(定义为估算肾小球滤过率<15 mL/min/1.73 m2)或需要透析、肾功能恶化和蛋白尿变化的复合结局。
- 基于糖尿病状态、CKD和单个GLP-1受体激动剂药物进行亚组分析。
- 采用随机效应模型合并各试验的相对风险(RR)及95%置信区间(CI)。
主要发现
- GLP-1受体激动剂使主要肾脏结局风险降低19%(RR 0.81,95%CI 0.73-0.89)。
- GLP-1受体激动剂使肾功能下降风险降低12%(RR 0.88,95%CI 0.81-0.95)。
- GLP-1受体激动剂使年肾功能下降减少0.45 mL/min/1.73 m2(16项试验,均数差(MD)0.45,95%CI 0.10-0.81)。
- GLP-1受体激动剂使微量白蛋白尿降低24%(RR 0.76,95%CI 0.71-0.82),HbA1c降低0.61%(MD -0.61,95%CI -0.76至-0.49),体重降低5 kg(MD -5.24,95%CI -7.46至-3.02)。
- 进展至肾衰竭无显著差异(RR 0.86,95%CI 0.71-1.05),但主要不良心血管事件降低15%(RR 0.85,95%CI 0.81-0.90),全因死亡率降低14%(RR 0.86,95%CI 0.82-0.91)。
局限性
- 需要进一步开展高质量随机试验,评估GLP-1受体激动剂在无糖尿病患者、伴或不伴蛋白尿和/或CKD患者中的效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND HYPOTHESIS: Glucagon-like peptide-1 receptor agonists (GLP1-RAs) are anti-hyperglycaemic agents, with cardioprotective effects, however their renal protective effects remain unclear. We aimed to assess the effects of GLP1-RAs on renal outcomes in patients with or without diabetes. METHODS: We performed a systematic review and meta-analysis with Medline, EMBASE and the Cochrane Register searched to December 2024. The primary outcome was the composite of kidney failure (defined as estimated glomerular filtration rate <15 mL/min/1.73 m2) or dialysis requirement, worsening of renal function and changes in proteinuria. Subgroup analysis was performed based on diabetic status, a (CKD) and individual GLP1-RA drugs. Relative risks (RR) with 95% confidence intervals (CI) for individual trials were pooled using random effects models. RESULTS: We identified 19 trials including 90 882 patients. Mean age was 60.8 years and mean follow-up was 25.9 months. GLP1-RAs were associated with a 19% reduction in the risk of primary renal outcome (RR 0.81, 95% CI 0.73-0.89), a 12% reduction in renal functional decline (RR 0.88, 95% CI 0.81-0.95) and a 0.45 mL/min/1.73 m2 reduction in yearly loss [16 trials, mean difference (MD) 0.45, 95% CI 0.10-0.81]. GLP1-RAs also reduced microalbuminuria by 24% (RR 0.76, 95% CI 0.71-0.82), HbA1c (units: %) by 0.61 (MD -0.61, 95% CI -0.76 to -0.49) and body weight by 5 kg (MD -5.24, 95% CI -7.46 to -3.02). Although there were no significant differences in progression to kidney failure (RR 0.86, 95% CI 0.71-1.05), GLP1-RAs reduced the incidence of major adverse cardiovascular events by 15% (RR 0.85, 95% CI 0.81-0.90) and all-cause mortality by 14% (RR 0.86, 95% CI 0.82-0.91). No significant differences were seen in severe adverse events (RR 0.96, 95% CI 0.90-1.01). However, there were more gastroenterological side effects. CONCLUSIONS: GLP1-RAs demonstrated cardiovascular and renal benefits. Further high-quality randomized trials assessing their effects in patients without diabetes, with or without proteinuria and/or CKD are needed.
引用
- Sasaki T, Giang SM, Wu J, et al. The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2026. PMID: 40982219. doi:10.1093/ndt/gfaf193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。